NOVENTRA PHARMA – RETATRUTIDE 32 mg
R1 750,00
Triple hormone receptor agonist (GIP + GLP-1 + glucagon) Considered
the next generation after Tirzepatide with stronger weight-loss effects.
• More potent appetite suppression and fat loss than semaglutide or
tirzepatide (shown in early studies).
• Self-mixed vial allows precise micro-dosing with insulin syringes.
• Discard vial 30–45 days after reconstitution, even
if not finished.
• Store unmixed powder vials in a cool, dark place
until ready.
Description
Week 3 5 mg 33 units
Week 4 7.5 mg 50 units
Week 5 7.5 mg 50 units
Maintenance 7.5 mg 50 units
This is a transcription of the supplier’s advertisement, not a medically validated dosing guide.
Please be aware:
Retatrutide remains an investigational medicine and is not approved for routine weight-loss treatment.
Its safety and effectiveness are still being studied.
The advertised dosing schedule is not an established clinical protocol.
Product authenticity, sterility and concentration must be independently verified.
Do not use this advertised mixing or dosing schedule without advice from a qualified medical professional.
Reviews
There are no reviews yet.